Clarus Therapeutics Closes Transaction With Blue Water, Debuts as a Publicly Traded Company to Develop Androgen and Metabolic Therapies
09 sept. 2021 12h46 HE
|
Clarus Therapeutics, Inc.; Blue Water Acquisition Corp.
Business combination with Blue Water Acquisition Corp., a special purpose acquisition company, completed on September 9, 2021 Combined company to be renamed Clarus Therapeutics Holdings, Inc. Clarus...
Clarus Therapeutics Announces Comprehensive Settlement of Patent Litigation With Lipocine
15 juil. 2021 09h00 HE
|
Clarus Therapeutics, Inc.
NORTHBROOK, Ill., July 15, 2021 (GLOBE NEWSWIRE) -- Clarus and Lipocine (NASDAQ: LPCN) agreed to settle all outstanding claims in the patent infringement lawsuit brought against Clarus by Lipocine...
Clarus Announces JATENZO® (Testosterone Undecanoate) Capsules, CIII Now Covered by Express Scripts
07 déc. 2020 09h00 HE
|
Clarus Therapeutics, Inc.
JATENZO is the first and only FDA-approved oral testosterone replacement therapy of its kind Coverage effective December 1, 2020 on the Express Scripts National Preferred, Basic and High Performance...
CLARUS THERAPEUTICS ANNOUNCES FINANCING TO SUPPORT THE COMMERCIAL LAUNCH AND AVAILABILITY OF JATENZO® (TESTOSTERONE UNDECANOATE) CAPSULES, CIII FOR THE TREATMENT OF HYPOGONADISM
16 mars 2020 08h00 HE
|
Clarus Therapeutics, Inc.
Financing to speed commercialization of the only FDA-approved oral treatment of its kind for testosterone deficiency1,2 NORTHBROOK, Ill., March 16, 2020 (GLOBE NEWSWIRE) -- Clarus Therapeutics,...
Clarus Therapeutics Announces Commercial Launch and Availability of JATENZO® (testosterone undecanoate) capsules, CIII for the Treatment of Hypogonadism
10 févr. 2020 08h00 HE
|
Clarus Therapeutics, Inc.
First and only FDA-approved oral treatment of its kind for testosterone deficiency1,2 NORTHBROOK, Ill., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc. today announced that JATENZO®...
Clarus Therapeutics Expands Executive Team in Preparation for Landmark Launch of JATENZO® (testosterone undecanoate) Capsules CIII
11 déc. 2019 14h04 HE
|
Clarus Therapeutics, Inc.
NORTHBROOK, Ill., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc. today announced the appointment of five senior leaders, each of whom bring valuable industry and category experience to...
Lipocine Withdraws Preliminary Injunction Threat Against Marketing of Clarus Therapeutics’ JATENZO® Product: Trial Date Set for August 2020
26 août 2019 08h30 HE
|
Clarus Therapeutics, Inc.
NORTHBROOK, Ill., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Clarus today announced that Lipocine, Inc. has confirmed that it will not seek preliminary injunctive relief against Clarus in a lawsuit that...
Clarus Therapeutics Announces FDA Award of 3-Year Market Exclusivity for Jatenzo®
19 août 2019 08h30 HE
|
Clarus Therapeutics, Inc.
JATENZO® is a first-in-class proprietary softgel oral formulation of testosterone undecanoate for testosterone replacement therapy in certain adult hypogonadal men and the first oral testosterone...
Clarus Therapeutics Refutes Patent Infringement Complaint
03 avr. 2019 10h05 HE
|
Clarus Therapeutics, Inc.
NORTHBROOK, Ill., April 03, 2019 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc. today announced that it will vigorously defend itself against an action brought by Lipocine, Inc. for patent...
Clarus Therapeutics Receives U.S. FDA Approval of JATENZO® (Testosterone Undecanoate Capsules for Oral Use) (CIII) for Testosterone Replacement Therapy in Certain Adult Men
27 mars 2019 16h27 HE
|
Clarus Therapeutics, Inc.
JATENZO is a first-in-class proprietary softgel oral formulation of testosterone undecanoate for testosterone replacement therapy in certain adult men, and the first oral testosterone medicine...